Pressure injuRy preventiOn by inTermittent EleCtrical sTimulation (PROTECT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04328246 |
Recruitment Status :
Terminated
(Recruitment was not feasible at site.)
First Posted : March 31, 2020
Last Update Posted : January 11, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pressure Injury | Device: IES System Other: Standard of Care Therapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 4 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The PROTECT Study: Pressure injuRy preventiOn by inTermittent EleCtrical sTimulation |
Actual Study Start Date : | February 26, 2021 |
Actual Primary Completion Date : | March 14, 2022 |
Actual Study Completion Date : | March 14, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: IES Device + Standard of Care
Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
|
Device: IES System
The IES system is composed of a stimulator and self-adhesive surface gel electrodes. Other: Standard of Care Therapy Standard institutional practices for treating pressure injury. |
Active Comparator: Standard of Care
Standard of care treatment for pressure injuries is turning the patient every two hours.
|
Other: Standard of Care Therapy
Standard institutional practices for treating pressure injury. |
- Clinical course of pressure injury over time [ Time Frame: Patients will be assessed daily for pressure injury location and stage through treatment completion, an average of 14 days. ]Chauhan Weighted Trajectory Analysis (CWTA) will be used to compare the morbidity associated with sacral and ischial pressure injuries through time. A one-sided Chauhan logrank test at a significance of 0.05 will be used to assess for superiority of the experimental arm over the control arm.
- Clinical course of pressure injury in subgroups [ Time Frame: Patients will be assessed daily for pressure injury location and stage through treatment completion, an average of 14 days. ]Chauhan Weighted Trajectory Analysis (CWTA) will be used to compare the morbidity associated with sacral and ischial pressure injuries through time. A one-sided Chauhan logrank test at a significance of 0.05 will be used to assess superiority.
- Kaplan-Meier Time-to-Event Analysis [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]A Kaplan Meier Curve and logrank Test (one-sided significance at p < 0.05) will be used to evaluate a difference in sacral and ischial pressure injury time-to-event morbidity between groups. An "event" is defined as the development of any stage/class of pressure ulcer.
- Cox Regression Analysis [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]Cox-regression analysis will be used to determine whether the implementation of the IES device is associated with a significant difference in sacral and ischial pressure injury time-to-event occurrence between treatment groups.
- Observed Counts of Pressure Injuries [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]Descriptive statistics and Chi-square testing will be used to compare in incidence rates and proportion between the treatment groups for sacral and ischial pressure injuries classified as Stage I-IV or Unstageable
- Onset Time [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]Descriptive statistics will be used to report the central tendency and spread of the onset time of a sacral and ischial pressure injury for both treatment groups and for injuries classified as Stage I-IV or Unstageable
- Relative Risk [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]Relative risk of sacral and ischial pressure injuries will be compared between treatment groups using a 2x2 contingency table with a 95% confidence interval.
- Duration of Inpatient Stay [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]Descriptive statistics will be used to report the central tendency and spread of the duration of inpatient stay for both treatment groups
- Description of adverse events related to IES [ Time Frame: Final analysis will be performed at end of study (expected completion 2 years) ]We will report frequency and severity of skin changes underlying the electrodes, categorized as i) transient erythema after electrode removal, ii) non-transient skin changes after electrode removal, iii) skin breakdown under electrode.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Modified Braden Scale score of 14 or less. The Modified Braden Scale score is calculated as follows:
Braden Scale score (Ranges from 6 to 23)
- 1 for Low Serum Albumin
- 1 for Type II Diabetes
- Anticipated length of stay of at least 4 days
- BMI < 35
- Participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf.
Exclusion Criteria:
- Existing pressure injuries above Stage II and injuries classified as DTI or unstageable
- Neuromuscular blocking drugs & myasthenia gravis: may prevent the ability of electrical stimulation to induce muscular contraction
- Unstable spinal, pelvic, or hip fractures that may be displaced by a forced contraction
- Rhabdomyolysis
- Use of a Pacemaker
- Skin breakdown over the gluteal regions that would preclude the use of surface electrodes.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04328246
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada, T6G 1Z2 |
Responsible Party: | AHS Cancer Control Alberta |
ClinicalTrials.gov Identifier: | NCT04328246 |
Other Study ID Numbers: |
IIT-0018 |
First Posted: | March 31, 2020 Key Record Dates |
Last Update Posted: | January 11, 2023 |
Last Verified: | March 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Wounds and Injuries Crush Injuries |